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Association of BodyMass Index and AgeWith Subsequent
Breast Cancer Risk in PremenopausalWomen
The Premenopausal Breast Cancer Collaborative Group
IMPORTANCE The association between increasing bodymass index (BMI; calculated as weight
in kilograms divided by height in meters squared) and risk of breast cancer is unique in cancer
epidemiology in that a crossover effect exists, with risk reduction before and risk increase
after menopause. The inverse association with premenopausal breast cancer risk is poorly
characterized but might be important in the understanding of breast cancer causation.
OBJECTIVE To investigate the association of BMI with premenopausal breast cancer risk, in
particular by age at BMI, attained age, risk factors for breast cancer, and tumor characteristics.
DESIGN, SETTING, AND PARTICIPANTS Thismulticenter analysis used pooled individual-level
data from 758 592 premenopausal women from 19 prospective cohorts to estimate hazard
ratios (HRs) of premenopausal breast cancer in association with BMI from ages 18 through 54
years using Cox proportional hazards regression analysis. Median follow-up was 9.3 years
(interquartile range, 4.9-13.5 years) per participant, with 13 082 incident cases of breast
cancer. Participants were recruited from January 1, 1963, through December 31, 2013, and
data were analyzed from September 1, 2013, through December 31, 2017.
EXPOSURES Bodymass index at ages 18 to 24, 25 to 34, 35 to 44, and 45 to 54 years.
MAIN OUTCOMES ANDMEASURES Invasive or in situ premenopausal breast cancer.
RESULTS Among the 758 592 premenopausal women (median age, 40.6 years; interquartile
range, 35.2-45.5 years) included in the analysis, inverse linear associations of BMI with breast
cancer risk were found that were stronger for BMI at ages 18 to 24 years (HR per 5 kg/m2
[5.0-U] difference, 0.77; 95% CI, 0.73-0.80) than for BMI at ages 45 to 54 years (HR per
5.0-U difference, 0.88; 95% CI, 0.86-0.91). The inverse associations were observed even
among nonoverweight women. There was a 4.2-fold risk gradient between the highest and
lowest BMI categories (BMI35.0 vs <17.0) at ages 18 to 24 years (HR, 0.24; 95% CI,
0.14-0.40). Hazard ratios did not appreciably vary by attained age or between strata of other
breast cancer risk factors. Associations were stronger for estrogen receptor–positive and/or
progesterone receptor–positive than for hormone receptor–negative breast cancer for BMI
at every age group (eg, for BMI at age 18 to 24 years: HR per 5.0-U difference for estrogen
receptor–positive and progesterone receptor–positive tumors, 0.76 [95% CI, 0.70-0.81] vs
hormone receptor–negative tumors, 0.85 [95% CI: 0.76-0.95]); BMI at ages 25 to 54 years
was not consistently associated with triple-negative or hormone receptor–negative breast
cancer overall.
CONCLUSIONS AND RELEVANCE The results of this study suggest that increased adiposity is
associated with a reduced risk of premenopausal breast cancer at a greater magnitude than
previously shown and across the entire distribution of BMI. The strongest associations of risk
were observed for BMI in early adulthood. Understanding the biological mechanisms
underlying these associations could have important preventive potential.
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B reast cancer is the most commonly diagnosed canceramong women worldwide, accounting for 25% of fe-male cancer cases at all ages and a greater percentage
among young women.1 Its complex etiology involves an un-
usually large range of factors, of which adiposity, often as-
sessed as bodymass index (BMI; calculated as weight in kilo-
grams divided by height inmeters squared), is important and
appears to have opposing effects at premenopausal and post-
menopausal ages.
Increasedadiposity inchildhoodandbeforemenopausehas
been reported to be inversely associatedwith the risk of breast
cancerdiagnosedatpremenopausal andpostmenopausal ages,
whereas increased adiposity after menopause is positively as-
sociatedwithrisk.2-11However,becauseincidenceratesarelower
among premenopausal than postmenopausal women, indi-
vidual studies have had limited ability to investigate the asso-
ciationofBMIwiththeriskofpremenopausalbreastcancer.Past
studies have been case-control studies, with potential for bias,
andmostprospectivestudieshavehadmodestnumbersofcases,
except for some recent studies in Asian12,13 or Jewish Israeli14
populations, but have not assessed risk at different ages, by tu-
mor type, andbymenopausal status atbreast cancerdiagnosis.
Meta-analyseshaveaggregatedstudiesthatdifferedinageatBMI
assessment, attained age of participants, and degree of adjust-
ment for potential confounding, and resultswere not stratified
byother risk factors.2-5,15-18 Somestudies suggest that theasso-
ciation of premenopausal adiposity with risk varies by tumor
characteristics,2,7,17-19 but larger studies are needed to provide
stable estimates by hormone receptor status or intrinsic tumor
subtype.
To undertake amore powerful and systematic analysis of
the association of BMI with breast cancer risk in premeno-
pausal women,we pooled individual-level data from 758592
women, including 13082 cases of breast cancer, from 19 pro-
spective cohort studies using data from recruitment and fol-
low-upquestionnaires.We aimed to estimate the relative risk
associatedwith BMI at different ages, age at breast cancer di-
agnosis, and breast cancer characteristics and to explore
whether associations were modified by other risk factors for
breast cancer.
Methods
Information on the Premenopausal Breast Cancer Collabora-
tive Group, a collaboration facilitated by the National Cancer
InstituteCohortConsortium,hasbeenpublishedpreviously.20
In short, individual-level data were pooled from 19 prospec-
tive cohorts in North America (n = 9), Europe (n = 7), Asia
(n = 2), andAustralia (n = 1),20withparticipants recruited from
January 1, 1963, through December 31, 2013 and at least 100
breast cancer casesdiagnosedbefore55yearsof age.Datawere
harmonized to a common template for 1 to 16 questionnaire
rounds per study. Full details of the study cohorts are given
in the eMethods in the Supplement. All contributing studies
gained approval from institutional review boards and ob-
tained consent from participants as per country-specific re-
quirements.
We used information on self-reported or measured cur-
rentweightandheight frommultiplequestionnaire roundsand
information reported on questionnaires about weight at ages
before study entry to construct BMI within the age ranges of
18 to 24, 25 to 34, 35 to 44, and 45 to 54 years.We categorized
BMIaccording toWorldHealthOrganizationdefinitions.21 The
analysis included all participants who were premenopausal,
had no personal history of breast cancer at study entry, and
had data for premenopausal BMI available.
All breast cancers included in this analysis occurred be-
fore menopause, with the main analytic end point being in-
vasive or in situ premenopausal breast cancer overall. How-
ever,wealsoanalyzedseparatelyby invasiveand insitucancer,
by immunohistochemistrydata onestrogen receptor (ER) and
progesteronereceptor (PR)status,andbyclinicopathologic sur-
rogate definitions of intrinsic breast cancer subtype.
Hazard ratios (HRs)wereobtainedas estimatesof the rela-
tive risk of breast cancer from Cox proportional hazards re-
gressionmodels22 with attained age as the underlying times-
cale. Follow-up for breast cancer started at study entry or the
age after enrollment to which the BMI applied. Follow-up
ended at breast cancer diagnosis, menopause (or hysterec-
tomy), last follow-up, death, or age 55 years, whichever oc-
curred first.
We first generated cohort-specific relative risk estimates
and obtained a pooled estimate with a 2-stage model.23 Be-
cause no appreciable between-study heterogeneity was de-
tectedusingthe I2 statistic,24 thedatawereanalyzed inapooled
data set. All presented analyseswere adjusted for attainedage
(implicit in the Cox proportional hazards regression model),
cohort, year of birth, age at menarche, age at first birth, time
since last birth, parity, and familyhistory of breast cancer. Co-
variate informationwas timeupdated,whenpossible,with in-
formation from follow-up questionnaires.
We analyzed BMI separately as categorical and continu-
ous variables (per 5 kg/m2 [5.0-U] difference), assuming a log-
linear dose-response association, the validity of which was
checked using restricted cubic splinemodels.25We tested for
effectmodification by other risk factors for breast cancer and
by attained age using log-likelihood ratio tests.26 Analyses by
breast tumor subtype were conducted using an augmenta-
tionmethod.27 Thismethodallowsestimationof separate risk
Key Points
Question What is the association between bodymass index and
risk for breast cancer diagnosed before menopause?
Finding In this large pooled analysis of data on 758 592
premenopausal women, an inverse association of breast cancer
risk with bodymass index at 18 through 54 years of age was found,
most strongly for bodymass index at ages 18 through 24 years.
The inverse association was strongest for hormone
receptor–positive breast cancer, was evident across the entire
distribution of bodymass index, and did not materially vary by
attained age or other characteristics of women.
Meaning Increased adiposity, in particular during early adulthood,
may be associated with reductions in the risk of premenopausal
breast cancer.
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factorassociations for type-specificoutcomes inasinglemodel
stratified on outcome type, obtained from a data set inwhich
separate observations on each participant have been created
for each outcome. Conducted sensitivity analyses are out-
lined in the eMethods in the Supplement.We used Stata, ver-
sion 14.2 (StataCorp) for all analyses, with P < .05 indicating
signficance.28
Results
The analyses included 758 592 women (median age, 40.6
years; interquartile range, 35.2-45.5 years), among whom
13082 in situ or invasive breast cancer cases occurred dur-
ing 7.2 million premenopausal years of follow-up (me-
dian, 9.3 years; interquartile range, 4.9-13.5 years) (eTable 1
in the Supplement). Weight was provided at 1 to 14 (me-
dian, 2) follow-up rounds per study and was self-reported
for 88.9% to 99.6% of weights, depending on age. Weight at
ages 18 to 24 years was retrospectively reported for 96.9%
and at later ages for less than 10% of women. Obesity
(BMI≥30.0) was more common in women who were 45
years or older (11.1%), were nulliparous (12.4%), had an early
menarche (17.0%), had a family history of breast cancer
(12.8%), or were black (26.8%) (Table).
IncreasingBMIwas linearlyassociatedwithdecreasing risk
of breast cancer in the restricted cubic spline models (eFig-
ures 1 and2 in theSupplement), except that, for someages and
tumor types, there appeared to be a leveling of risk for under-
weight women (BMI<18.5) compared with those in the nor-
malweight range (BMI, 18.5-24.9).We therefore restricted the
linear modeling of BMI to values of 18.5 or greater.
Hazard ratios for breast cancer decreasedwith increasing
BMI category (Figure 1), more for BMI at younger than older
ages, with a risk reduction of 23% per 5.0-U difference
(HR, 0.77; 95%CI,0.73-0.80) forBMIat ages 18 to24years and
12% (HR, 0.88; 95% CI, 0.86-0.91) for BMI at 45 to 54 years.
The risk gradient was 4.2-fold between the highest and low-
est BMI categories (BMI≥35.0 vs <17.0) at ages 18 to 24 years
(HR, 0.24; 95%CI, 0.14-0.40). Significant differences in rela-
tive riskwerepresent evenwithin thenormal rangeofBMI (for
23.0-24.9 vs 18.5-22.9: HR,0.80; 95%CI, 0.75-0.86). TheHRs
for BMI at ages 18 to 24 years remained statistically signifi-
cant after additional adjustment formost recent BMI (HR per
5.0-U increase, 0.80; 95%CI, 0.76-0.84).We foundno appre-
ciable heterogeneity in the associationbetween studies (eFig-
ure 3A-D in the Supplement).
Weight at ages 18 to 24 years was correlated with
weights at older ages (r = 0.70 for ages 25-34, r = 0.63 for
ages 35-44, and r = 0.55 for ages 45-54 years). When we
adjusted the analyses of breast cancer risk in Figure 2 for
BMI at ages 18 to 24 years, the HRs per 5.0-U increase were
0.92 (95% CI, 0.88-0.97) for BMI at ages 25 to 34 years, 0.93
(95% CI, 0.91-0.96) at ages 35 to 44 years, and 0.91 (95% CI,
0.88-0.95) at ages 45 to 54 years (Figure 2 and eTable 2 in
the Supplement). The magnitude of the inverse associations
was similar between categories of attained age to age 55
years (eFigure 4 in the Supplement).
Incident cases of breast cancer included 10836 invasive
and2138 insitubreast cancers.Associationswith riskper5.0-U
difference inBMIwere significantly larger for in situ (HR, 0.76;
95% CI, 0.69-0.85) than for invasive breast cancer (HR, 0.88;
95%CI, 0.84-0.92) (P = .02 for interaction) for BMI at ages 25
to 34 years; difference in associations were also found for in
situ (HR, 0.81; 95% CI, 0.76-0.86) and invasive breast cancer
(HR, 0.88; 95% CI, 0.86-0.90; P = .01 for interaction) at 35 to
44 years (eTable 3 in the Supplement). The percentage of all
breastcancers thatwere insitudidnotappreciablyvarybyBMI,
and women with higher BMI were more likely to have had a
screening mammogram (eTable 4 in the Supplement).
The ER and/or PR status was known for 7812 cases, 7002
(89.6%)ofwhichwere invasive.Wedidnot observe consistent
significantdifferences inHRs forER-positivevsER-negativeor
PR-positivevsPR-negativebreastcancer (eTable5 intheSupple-
ment).WhenconsideringERandPR jointly,ER-positiveand/or
PR-positivebreastcancershowedstrongerassociationswithBMI
at ages 18 to 24 years (eg, for ER-positive and PR-positive, HR,
0.75; 95% CI, 0.70-0.81) than did hormone receptor–negative
breast cancer; however, the associationwas still significant for
ER-negative and PR-negative breast cancer (HR, 0.85; 95% CI,
0.76-0.95) (eFigure 5 in the Supplement). Bodymass index at
older ages was not associated with hormone receptor–
negative breast cancer risk. In analyses by intrinsic breast can-
cer subtype (Figure 3), the nonluminal (ER-negative and PR-
negative) subtypewas inversely associatedwithBMIat ages 18
to24(HR,0.86;95%CI,0.77-0.96)and45to54years (HR,0.90;
95%CI, 0.84-0.98), but notwith BMI at ages 25 to 34 and 35 to
44 years. No association of BMI at 25 years or olderwith triple-
negativebreastcancerorofBMIat35yearsorolderwithERBB2/
HER2-enriched breast cancer was found.
Hazard ratios per 5.0-Udifference inBMIwerenot signifi-
cantly different between strata of most risk factors for breast
cancer, including race/ethnicity (forBMI at ages 18 to24years:
HR for black women, 0.84 [95% CI, 0.76-0.93]; HR for Asian
women, 0.69 [95% CI, 0.40-1.18]; and HR for white women,
0.73 [95%CI,0.70-0.77];P = .08 for interaction) (eFigure6and
eTable 6 in the Supplement). Hazard ratios were greater for
never users comparedwith than ever users of oral contracep-
tives (atbaseline formost studies) forBMIat ages 18 to24years
(HR, 0.68 [95% CI, 0.61-0.76] vs 0.79 [95% CI, 0.75-0.83];
P = .02 for interaction) and ages 35 to 44 (HR, 0.81 [95% CI,
0.77-0.86] vs 0.88 [95% CI, 0.86-0.91]; P = .009 for interac-
tion). The HR was also greater for nulliparous than parous
women (HR, 0.79 [95% CI, 0.73-0.87] vs 0.88 [95% CI, 0.84-
0.93]; P = .03 for interaction) for BMI at ages 25 to 34 years.
Results were not materially affected in the sensitivity analy-
ses (eTables 7-9 in the Supplement) except for those shown in
Figure 1.
Discussion
In this large prospective analysis investigating the associa-
tion between adiposity and breast cancer risk in premeno-
pausal women, we analyzed relative risk by BMI in a larger
number of categories than possible in previous studies,
Association of BodyMass Index and AgeWith Subsequent Breast Cancer Risk in Premenopausal Women Original Investigation Research
jamaoncology.com (Reprinted) JAMAOncology Published online June 21, 2018 E3
Downloaded From:  by Institute of Cancer Research UK, minouk schoemaker on 06/22/2018
revealing a 4.2-fold risk gradient between women who were
underweight vs obese at ages 18 to 24 years and a 1.9- to 2.5-
fold risk gradient between these BMI categories at later ages.
Wedemonstrated that the inverseassociationsapply to theen-
tire distribution of BMI, with risk variations evident even
among women in the nonoverweight range of BMI.
The observed inverse associations are unlikely to be at-
tributable tobias,giventhat theywerepresent inmultiplestud-
Table. Characteristics at Study Recruitment ofWomen Included in the Analyses
Characteristic
Participants,
No. (BMI≥30.0, %)
Person-years of Follow-up,
No. (%)a
Cancer Cases,
No.
BMIb
15.0-16.9 2843 29 293 (0.4) 53
17.0-18.4 20 245 221 540 (3.1) 442
18.5-24.9 499 146 4 901 964 (68.1) 9356
25.0-29.9 159 660 1 375 769 (19.1) 2257
30.0-34.9 51 413 442 769 (6.2) 678
35.0-49.9 25 285 227 485 (3.2) 296
Age at entry, y
<25 17 627 (9.2) 211 220 (2.9) 74
25-34 167 744 (8.9) 2 585 847 (35.9) 3657
35-44 366 893 (10.1) 3 688 360 (51.2) 7404
≥45 206 328 (11.1) 713 394 (9.9) 1947
Age at menarche, y
7-11 141 899 (17.0) 1 410 957 (19.6) 2712
12-13 391 822 (9.7) 3 849 467 (53.5) 7117
≥14 195 180 (6.2) 1 715 887 (23.8) 2871
Missing or no periods 29 691 (9.1) 222 509 (3.1) 382
Age at first birth, y
<25 290 668 (11.2) 2 630 694 (36.5) 4186
25-34 273 023 (8.7) 2 583 161 (35.9) 5364
≥35 19 152 (9.5) 134 836 (1.9) 393
Nulliparous 121 920 (12.4) 1 311 508 (18.2) 2367
Age or whether parous
unknown
53 829 (6.7) 538 621 (7.5) 772
No. of birthsc
1 128 760 (10.4) 1 358 259 (25.2) 2583
2 252 325 (9.4) 2 213 928 (41.0) 4356
3 188 633 (10.8) 1 650 219 (30.6) 2900
Not known 18 341 (6.5) 178 049 (3.3) 172
Family history of breast cancer
No 556 203 (10.1) 5 576 245 (77.5) 9478
Yes 75 299 (12.8) 625 576 (8.7) 2265
Not known 127 090 (8.4) 997 000 (13.8) 1339
Race/ethnicity
White 419 130 (10.0) 4 437 300 (61.6) 8437
Black 52 903 (26.8) 586 734 (8.2) 1006
Asian 26 214 (2.5) 212 411 (3.0) 235
Other 7894 (13.7) 89 276 (1.2) 167
Not known 252 451 (7.5) 1 873 100 (26.0) 3237
Birth cohort
Before 1930 23 849 (9.1) 98 669 (1.4) 178
1930-1939 66 110 (7.7) 655 904 (9.1) 1306
1940-1949 243 663 (8.4) 1 878 359 (26.1) 4088
1950-1959 282 307 (10.9) 2 983 715 (41.4) 5305
1960-1969 101 002 (13.7) 1 183 177 (16.4) 1970
1970-1979 33 904 (11.2) 341 589 (4.7) 219
1980 or later 7757 (8.1) 57 407 (0.8) 16
All 758 592 (10.1) 7 198 821 (100.0) 13 082
Abbreviation: BMI, bodymass index
(calculated as weight in kilograms
divided by height in meters squared).
a Percentages have been rounded
andmay not total 100. Owing to
rounding, person-years may not
sum to the total.
b Indicates at study entry or, if
missing, most recent retrospectively
reported weight.
c Includes parous only.
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ies and across strata of birth cohort and risk factors for breast
cancer.Too fewwomendiedduring follow-up (3.3%ofwomen
with a BMI≥35.0 vs 1.7%with BMI of 18.5-24.9) to explain the
inverse associations for death as a competing risk. Our results
are also supported as causal rather than artifactual by amen-
delian randomization study29 reporting genetically pre-
dicted BMI to be inversely associatedwith breast cancer risk.
The stronger inverse associations of risk with BMI at
younger thanolder ages suggest that adiposity inyoungadult-
hood or earlier, if adiposity at approximately 20 years of age
is a proxymarker for adiposity in childhood, is the critical fac-
tor. No cohorts in our collaboration had information on BMI
at younger than 18 years, but published analyses of subjec-
tivebodysize comparedwithpeers at theseages7-9have found
Figure 1. Relative Risk of Premenopausal Breast Cancer AssociatedWith
BMI Category, by Age at BMI
Less
Risk
BMI Category 
by Age
18-24 y
No. of 
Cases
Multivariable 
Adjusted HR 
(95% CI)
Greater
Risk
2.01.00.50.2
Multivariable-Adjusted
HR (95% CI)
15.0-16.9 328 1.15 (1.03-1.29)
17.0-18.4 1169 1.09 (1.02-1.16)
18.5-22.9 6364 1 [Reference]
23.0-24.9 864 0.80 (0.75-0.86)
25.0-27.4 418 0.73 (0.66-0.81)
27.5-29.9 141 0.68 (0.58-0.81)
30.0-32.4 81 0.73 (0.58-0.90)
32.5-34.9 25 0.47 (0.32-0.70)
35.0-49.9 15 0.27 (0.16-0.45)
Trend per 5-U 
difference in BMIa
7908 0.77 (0.73-0.80)
25-34 y
15.0-18.4 221 1.22 (1.06-1.40)
18.5-22.9 2222 1 [Reference]
23.0-24.9 607 0.91 (0.83-0.99)
25.0-27.4 403 0.82 (0.74-0.91)
27.5-29.9 176 0.76 (0.65-0.88)
30.0-32.4 101 0.67 (0.54-0.81)
32.5-34.9 58 0.63 (0.49-0.82)
35.0-37.4 38 0.67 (0.48-0.92)
37.5-39.9 24 0.64 (0.42-0.95)
25 0.49 (0.33-0.74)
Trend per 5-U 
difference in BMIa
3654 0.85 (0.82-0.89)
40.0-49.9
35-44 y 
15.0-18.4 318 1.05 (0.94-1.18)
18.5-22.9 5340 1 [Reference]
23.0-24.9 1882 0.91 (0.86-0.96)
25.0-27.4 1264 0.82 (0.77-0.88)
27.5-29.9 636 0.81 (0.74-0.88)
30.0-32.4 417 0.81 (0.73-0.90)
32.5-34.9 214 0.70 (0.61-0.80)
35.0-37.4 123 0.63 (0.53-0.75)
37.5-39.9 74 0.60 (0.48-0.76)
81 0.49 (0.39-0.61)
Trend per 5-U 
difference in BMIa
10 031 0.87 (0.85-0.89)
40.0-49.9
45-54 y
15.0-18.4 120 1.04 (0.87-1.25)
18.5-22.9 2484 1 [Reference]
23.0-24.9 1127 0.94 (0.87-1.01)
25.0-27.4 859 0.85 (0.79-0.92)
27.5-29.9 430 0.77 (0.69-0.85)
30.0-32.4 302 0.80 (0.71-0.90)
32.5-34.9 160 0.72 (0.61-0.84)
35.0-37.4 112 0.76 (0.63-0.92)
37.5-39.9 62 0.66 (0.52-0.86)
70 0.56 (0.44-0.71)
Trend per 5-U 
difference in BMIa
5606 0.88 (0.86-0.91)
40.0-49.9
Bodymass index (BMI) is calculated as weight in kilograms divided by height in
meters squared. Hazard ratios (HRs) were adjusted for attained age, cohort,
year of birth, age at menarche, age at first birth, number of births, time since
last birth, and family history of breast cancer.
a Represents linear trend per 5 kg/m2 (5.0-U) difference in BMI from 18.5 to
49.9.
Figure 2. Relative Risk of Premenopausal Breast Cancer AssociatedWith
BMI and Adjusted for BMI at Ages 18 to 24 Years, by Age at BMI
Less
Risk
BMI Category 
by Age
No. of 
Cases
Multivariable 
Adjusted HR 
(95% CI)
Greater
Risk
2.01.00.50.4
Multivariable-Adjusted
HR (95% CI)
25-34 y
15.0-18.4 187 1.16 (0.99-1.36)
18.5-22.9 1963 1 [Reference]
23.0-24.9 546 0.94 (0.86-1.04)
25.0-27.4 364 0.87 (0.77-0.97)
27.5-29.9 165 0.86 (0.73-1.02)
30.0-32.4 93 0.77 (0.62-0.96)
32.5-34.9 56 0.79 (0.60-1.04)
35.0-37.4 37 0.87 (0.62-1.23)
37.5-39.9 23 0.84 (0.55-1.29)
24 0.72 (0.46-1.11)
Trend per 5-U 
difference in BMIa
3271 0.92 (0.88-0.97)
40.0-49.9
35-44 y 
15.0-18.4 215 1.05 (0.92-1.21)
18.5-22.9 3845 1 [Reference]
23.0-24.9 1392 0.94 (0.88-1.00)
25.0-27.4 977 0.88 (0.82-0.95)
27.5-29.9 498 0.89 (0.81-0.98)
30.0-32.4 334 0.93 (0.82-1.04)
32.5-34.9 174 0.82 (0.70-0.96)
35.0-37.4 111 0.83 (0.69-1.01)
37.5-39.9 65 0.79 (0.62-1.02)
73 0.68 (0.53-0.87)
Trend per 5-U 
difference in BMIa
7469 0.93 (0.91-0.96)
40.0-49.9
45-54 y
15.0-18.4 63 1.11 (0.86-1.43)
18.5-22.9 1535 1 [Reference]
23.0-24.9 788 0.96 (0.88-1.05)
25.0-27.4 644 0.89 (0.81-0.98)
27.5-29.9 338 0.84 (0.74-0.94)
30.0-32.4 234 0.85 (0.74-0.98)
32.5-34.9 123 0.76 (0.63-0.92)
35.0-37.4 83 0.80 (0.63-1.00)
37.5-39.9 54 0.81 (0.61-1.07)
60 0.68 (0.52-0.90)
Trend per 5-U 
difference in BMIa
3859 0.91 (0.88-0.95)
40.0-49.9
Bodymass index (BMI) is calculated as weight in kilograms divided by height in
meters squared. Hazard ratios (HRs) were adjusted for attained age, cohort,
year of birth, age at menarche, age at first birth, number of births, time since
last birth, and family history of breast cancer as well as BMI at ages 18 to 24
years.
a Represents linear trend per 5 kg/m2 (5.0-U) difference in BMI from 18.5 to
49.9.
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strong inverse associations with premenopausal and post-
menopausal breast cancer risk.
Our estimated 12% to 23% reduction in premenopausal
breast cancer riskper5.0-Udifference inBMIdependingonage
is substantially stronger than that from meta-analyses,3-5,15,16
whichhave reported5%to9%reductions amongwomenover-
all without analysis by age at BMI, and a study reporting a 10%
reduction using measured BMI at ages 16 to 19 years.14 We ob-
served that associations of BMI and breast cancer risk did not
dependonattainedage.We foundnopreviousanalysesbypre-
menopausal attained age, but risk reductions with increased
early-lifeBMIhavebeenreportedtocontinueaftermenopause.7,8
The associations of BMI with risk also did not appear to be ap-
preciablymodified by risk factors for breast cancer later in life,
with the possible exception of nulliparity and oral contracep-
tive use.
The stronger associations of BMI at ages 25 to 44 years for
in situ than for invasive breast cancer might reflect type-
specific etiology or the association for in situ cancer being in
part attributable to an association of body size with breast
screeningattendance.However,we foundnoevidence for this
association, given thatpercentagesof in situ cancerwere simi-
lar across BMI groups.
No previous analyses of hormone receptor status–
specific breast cancer by BMI assessed at different premeno-
pausal ageshavebeenperformed, toourknowledge.We found
that hormone receptor–positive breast cancerwas associated
withBMIatall agesand thathormonereceptor–negativebreast
cancer overall was associatedwith BMI at ages 18 to 24 years,
but not consistently associated with BMI at later ages; meta-
analyses of ER- andPR-negative tumors15,17 have foundno as-
sociation, based on age at recruitment. The absence of an as-
sociation of triple-negative breast cancerwithBMI at 25 years
or older in our analysis is contrary to previous reports18,19 in-
dicatingan increased riskof this tumor typewithobesity;how-
ever, these reports were based on case-control studies18 and
a pooled analysis of women younger than 50 years based on
studies of mixed design19 and therefore are subject to poten-
tial biases that are of less concern in prospective cohorts. We
observed thatERBB2/HER2-enrichedbreast cancerwas asso-
ciated with BMI at 35 years or younger but not at later ages;
the Nurses’ Health Study, included in this analysis, previ-
ously reportedastrongassociationwithBMIat 18yearsof age,7
but we are not aware of studies investigating the association
with later premenopausal ages.
Obesityhasmanyadverse effects ongeneral health,30 and
we do not advocate weight gain as a preventative measure
against premenopausal breast cancer. However, understand-
ing the mechanistic action underlying the inverse associa-
tionof premenopausal adipositywithbreast cancer risk could
potentially identify modifiable pathways. Because the asso-
ciation with BMI at ages 18 to 24 years is significant for ER-
positive and ER-negative tumors, hormonal and nonhor-
monal mechanisms might be involved. Breast tissue is
particularly susceptible tocarcinogensbetweenmenarcheand
first childbirth,31 and the extent of this susceptibility may be
influenced by childhood adiposity. Increased adiposity has a
strongassociationwithearlypubertalonsetbutalso slowerpu-
bertal tempo,32 includingslowerpeakgrowth,33 and rapidado-
lescent growthhasbeenassociatedwith increasedbreast can-
cer risk.34 The estrogenic effects of being overweight in
childhood, when adipose tissue is the major site of estrogen
Figure 3. Relative Risk of Premenopausal Breast Cancer per 5 kg/m2
(5.0-U) Difference in BMI by Age at BMI and Breast Cancer Intrinsic
Tumor Subtype
Less
Risk
Age at BMI by Intrinsic 
Cancer Subtype
No. of 
Cases
HRa per 5.0-U 
Difference 
(95% CI)
Greater
Risk
2.01.00.5
HR per 5.0-U 
Difference (95% CI)
BMI at ages 18-24 y
All luminal A-like 1467 0.73 (0.65-0.81)
All luminal B-like 949 0.73 (0.64-0.84)
Luminal B ERBB2/HER2 negative 259 0.74 (0.58-0.95)
Luminal B ERBB2/HER2 positive 371 0.84 (0.69-1.03)
All nonluminal 971 0.86 (0.77-0.96)
ERBB2/HER2 enriched 153 0.70 (0.49-1.00)
Triple negative 354 0.83 (0.70-0.99)
BMI at ages 25-34 y
All luminal A-like 789 0.78 (0.71-0.86)
All luminal B-like 452 0.89 (0.79-1.00)
Luminal B ERBB2/HER2 negative 122 0.90 (0.72-1.13)
Luminal B ERBB2/HER2 positive 186 0.95 (0.80-1.13)
All nonluminal 472 1.00 (0.91-1.09)
ERBB2/HER2 enriched 78 0.62 (0.43-0.89)
Triple negative 175 1.00 (0.86-1.17)
BMI at ages 35-44 y
All luminal A-like 1782 0.88 (0.84-0.93)
All luminal B-like 1219 0.80 (0.75-0.86)
Luminal B ERBB2/HER2 negative 314 0.79 (0.69-0.91)
Luminal B ERBB2/HER2 positive 421 0.93 (0.84-1.03)
All nonluminal 1169 0.97 (0.92-1.03)
ERBB2/HER2 enriched 168 0.91 (0.79-1.06)
Triple negative 407 0.94 (0.85-1.03)
BMI at ages 45-54 y
All luminal A-like 1117 0.96 (0.90-1.01)
All luminal B-like 759 0.79 (0.73-0.86)
Luminal B ERBB2/HER2 negative 188 0.84 (0.72-0.98)
Luminal B ERBB2/HER2 positive 237 0.93 (0.82-1.06)
All nonluminal 631 0.90 (0.84-0.98)
ERBB2/HER2 enriched 89 0.99 (0.83-1.19)
Triple negative 219 0.98 (0.87-1.11)
Bodymass index (BMI) is calculated as weight in kilograms divided by height in
meters squared. The luminal A–like subtype includes estrogen receptor
(ER)–positive, progesterone receptor (PR)–positive, and ERBB2/HER2-negative
tumors; luminal B–subtype, all ER-positive and/or PR-positive tumors that are
not luminal A–like (subtypes luminal B–like ERBB2/HER2-negative and luminal
B–like ERBB2/HER2-positive); and nonluminal subtype, all ER-negative and
PR-negative tumors, regardless of ERBB2/HER2 status (subtypes ERBB2/HER2
enriched: ER-negative, PR-negative, and ERBB2/HER2-positive; triple-negative:
ER-negative, PR-negative, and ERBB2/HER2-negative).
a Represents linear trend per 5.0-U of difference in BMI from 18.5 to 49.9 and
are adjusted for attained age, cohort, year of birth, age at menarche, age at
first birth, number of births, time since last birth, and family history of breast
cancer. Estimates were obtained from 2 augmentationmodels.27 The first
model included luminal A–like, luminal B–like, and nonluminal breast cancer as
end points with tests for heterogeneity in effect by tumor type (for BMI at
ages 18-24 years, P = .07; at ages 25-34 years, P = .002; at ages 35-44 years,
P < .001; at ages 45-54, P < .001). Estimates for subtypes of luminal B–like and
nonluminal breast cancer were obtained from a secondmodel fitting luminal
A–like, luminal B–like ERBB2/HER2-positive, luminal B–like ERBB2/HER2-
negative, ERBB2/HER2-enriched, and triple-negative breast cancer as end
points.
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release, have been proposed to induce early breast differen-
tiation or to increase the expression of tumor suppressor
genes.35 Being underweight during adolescence, in contrast,
might result in immature differentiation due to lack of breast
fat and/or low levels of ovarian hormones during breast
development.36
Early-adulthood adiposity is associated with intermedi-
ate markers of breast cancer risk, such as benign breast
disease,37mammographicdensity,38andinsulinlikegrowthfac-
tor 1 levels.39Greatermammographicdensityhasapositiveas-
sociation with breast cancer risk,40 and amore endomorphic
somatotype inchildhoodandearlyadulthoodisassociatedwith
lowermammographicdensity throughout adulthood.38 In the
Nurses’HealthStudy,4182%of theassociationofBMIat 18years
of age with breast cancer risk was explained by mammo-
graphicdensity, andbreastdensitymaybean intermediate fac-
tor in the biological pathway for breast cancer development.
However, themechanismofhowdensityaffects risk isnotwell
understood,andtheamountofnondense (ie, fatty) tissue,with
which BMI is strongly correlated, is also inversely associated
withbreast cancer risk, independentlyofpercentagedensity.40
Early-life body size might also affect long-term insulinlike
growth factor 1 levels implicated in breast cancer risk,42 given
that plasma insulinlike growth factor 1 levels at ages 32 to 70
yearswere reported tobe 14% lower inwomenwhowereover-
weight comparedwith those whowere lean at age 18 years.39
The inverse association of BMI in premenopausalwomen
25 years or older with predominantly hormone receptor–
positive rather than hormone receptor–negative breast can-
cer implies a hormonal mechanism. Estrogen synthesis,
through the aromatase enzyme in subcutaneous fat, repre-
sents about 5% of total estradiol synthesis in premenopausal
women,butwithextremeobesity,negative feedback in thehy-
pothalamic-pituitary-axis can leadtoswitchoffofnormalovar-
ian function andbe reflected in amenorrhea.43 Irregularmen-
strual or fewerovulatory cycleshave thereforebeensuggested
aspossible explanations for the inverse association,44 but this
suggestion has not been supported by studies that could ad-
just formenstrual cycle pattern.9-11 However, BMI-relateddif-
ferences in sex-hormone profile may contribute to the in-
verse association of BMI and breast cancer risk. A study45
reported that premenopausal women with higher BMI had
lowerestradiol, total testosterone, sexhormone–bindingglobu-
lin, and progesterone levels but greater free testosterone lev-
els than premenopausal women with lower BMI. Positive as-
sociations of premenopausal breast cancer risk have been
reportedwith estradiol46-49 and testosterone levels,46-48,50,51
possibly stronger for ER-positive and/or PR-positive breast
cancer,47 but studies have been inconsistent. Studies investi-
gatingendogenousprogesterone levels,46,47,49-51however,have
not foundassociationswithbreast cancer risk. Circulating lev-
els of leptin, a peptide hormone produced primarily by adi-
pocytes that is overexpressed in breast cancer, were also as-
sociated with reduced premenopausal breast cancer risk in a
prospective study, although not independently from BMI.52
Strengths and Limitations
Thestrengthsof this collaborationare its largenumberofcases,
providing precise estimates of relative risk by age at adiposity
and allowing for stratified and breast cancer subtype–
specific analyses. All contributing studies were prospective,
and most had multiple follow-up rounds, facilitating deter-
minationofmenopausal statusand time-updatedcovariate in-
formation.
However, theuse of BMIhas its limitations in thatwomen
with the same BMI can have different body fat distributions
andoverall body fat levels.53 Bodymass indexwas recalled for
early adulthood, but a good correlation (r = 0.87) has been re-
ported between recalled and measured weight at 18 years of
age.54Currentweightwasusually self-reported, but in theSis-
ter Study,55 66% of women accurately reported their current
weightwithin 1.35kg,andunderweightwomentendedtoover-
report and obese women tended to underreport, although
rarely by more than 10%. If such misclassification applied to
all studies, we might have slightly overestimated the trends
but not to a sufficient degree to account for them fully. On the
other hand, random misclassification would have led to at-
tenuated effect sizes. Study-specific differences inmethodof
assessment and cut points for hormone receptor and ERBB2/
HER2 status of breast cancer, given that these data were fre-
quently obtained frommedical records, may have led to dif-
ferential classification of the tumor types between studies,
potentially leading to underestimation of relative risks. More
than 1000 breast cancer cases occurred in black women, al-
lowing for stable estimation of relative risks in that popula-
tion; results were similar to results fromwhite women. How-
ever, we had insufficient statistical power to address the
hypothesis thatassociationsmightbeweakerorabsent inAsian
populations.12,13,16,56
Conclusions
The results of our study suggest that increased BMI is in-
versely associatedwith the risk of breast cancer diagnosis be-
foremenopause, toagreatermagnitude thansuggested inpre-
vious analyses, andwith the strongest associations for BMI at
youngages.TheassociationwithBMI inearlyadulthood isuni-
versal across strata of other risk factors and across breast can-
cer subtypes. Understanding the biological mechanism un-
derlying this associationcouldhave important implications for
breast cancer prevention.
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